225 related articles for article (PubMed ID: 26993806)
1. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.
Hodson DJ; Shaffer AL; Xiao W; Wright GW; Schmitz R; Phelan JD; Yang Y; Webster DE; Rui L; Kohlhammer H; Nakagawa M; Waldmann TA; Staudt LM
Proc Natl Acad Sci U S A; 2016 Apr; 113(14):E2039-46. PubMed ID: 26993806
[TBL] [Abstract][Full Text] [Related]
2. Oct2 enhances antibody-secreting cell differentiation through regulation of IL-5 receptor alpha chain expression on activated B cells.
Emslie D; D'Costa K; Hasbold J; Metcalf D; Takatsu K; Hodgkin PO; Corcoran LM
J Exp Med; 2008 Feb; 205(2):409-21. PubMed ID: 18250192
[TBL] [Abstract][Full Text] [Related]
3. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
4. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
Sprowl JA; Ciarimboli G; Lancaster CS; Giovinazzo H; Gibson AA; Du G; Janke LJ; Cavaletti G; Shields AF; Sparreboom A
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11199-204. PubMed ID: 23776246
[TBL] [Abstract][Full Text] [Related]
6. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
[TBL] [Abstract][Full Text] [Related]
7. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
8. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
9. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
[TBL] [Abstract][Full Text] [Related]
10. Expression of the aldehyde dehydrogenase 2-like gene is controlled by BOB.1/OBF.1 in B lymphocytes.
Brunner C; Laumen H; Nielsen PJ; Kraut N; Wirth T
J Biol Chem; 2003 Nov; 278(46):45231-9. PubMed ID: 12947107
[TBL] [Abstract][Full Text] [Related]
11. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas.
Sáez AI; Artiga MJ; Sánchez-Beato M; Sánchez-Verde L; García JF; Camacho FI; Franco R; Piris MA
Mod Pathol; 2002 Mar; 15(3):211-20. PubMed ID: 11904338
[TBL] [Abstract][Full Text] [Related]
12. OBF1 and Oct factors control the germinal center transcriptional program.
Song S; Cao C; Choukrallah MA; Tang F; Christofori G; Kohler H; Wu F; Fodor BD; Frederiksen M; Willis SN; Jackson JT; Nutt SL; Dirnhofer S; Stadler MB; Matthias P
Blood; 2021 May; 137(21):2920-2934. PubMed ID: 33512466
[TBL] [Abstract][Full Text] [Related]
13. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
15. CRISP-3, a protein with homology to plant defense proteins, is expressed in mouse B cells under the control of Oct2.
Pfisterer P; König H; Hess J; Lipowsky G; Haendler B; Schleuning WD; Wirth T
Mol Cell Biol; 1996 Nov; 16(11):6160-8. PubMed ID: 8887646
[TBL] [Abstract][Full Text] [Related]
16. OCA-B integrates B cell antigen receptor-, CD40L- and IL 4-mediated signals for the germinal center pathway of B cell development.
Qin XF; Reichlin A; Luo Y; Roeder RG; Nussenzweig MC
EMBO J; 1998 Sep; 17(17):5066-75. PubMed ID: 9724642
[TBL] [Abstract][Full Text] [Related]
17. Oct2 and Obf1 as Facilitators of B:T Cell Collaboration during a Humoral Immune Response.
Corcoran L; Emslie D; Kratina T; Shi W; Hirsch S; Taubenheim N; Chevrier S
Front Immunol; 2014; 5():108. PubMed ID: 24688485
[TBL] [Abstract][Full Text] [Related]
18. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
19. Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.
Andrews JM; Pyfrom SC; Schmidt JA; Koues OI; Kowalewski RA; Grams NR; Sun JJ; Berman LR; Duncavage EJ; Lee YS; Cashen AF; Oltz EM; Payton JE
EBioMedicine; 2021 Sep; 71():103559. PubMed ID: 34461601
[TBL] [Abstract][Full Text] [Related]
20. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
